Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

TECHNOLOGY LICENSING OPPORTUNITY: Protein-Based Rare Earth Recovery via Condensation

Active
S-193669Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

Los Alamos National Laboratory has developed a bio-inspired protein system for selectively capturing and concentrating rare earth elements from complex liquid mixtures, offering a cleaner and more adaptable alternative to traditional, environmentally taxing extraction methods. The technology leverages an engineered version of Lanmodulin, a protein with high affinity for rare earths, modified by fusing an encapsulation peptide to its N-terminus. This modification enables the protein-metal complexes to self-assemble into separable biomolecular condensates upon binding target elements, allowing for straightforward recovery through centrifugation, filtration, or sedimentation without the need for immobilization on solid supports. The modular design permits swapping in different Lanmodulin variants optimized for specific rare earth targets, making the platform highly versatile across diverse feedstocks such as mining effluents, electronic waste streams, and industrial runoff. The system not only enables efficient concentration of rare earths but also allows for the recovery and reuse of the protein itself, enhancing sustainability and reducing operational costs. This innovation is positioned to support resilient supply chains for critical materials essential to energy storage, electronics, electric vehicles, and advanced manufacturing, aligning with growing demand for environmentally responsible processing techniques. It is designed for applications across critical minerals recovery, mining and mineral processing, waste recycling, environmental remediation, and biomanufacturing, with potential to transform how rare earths are extracted from low-grade or mixed sources. The technology is at Technology Readiness Level 3, with a U.S. patent pending, and is being offered for exclusive or non-exclusive licensing by the Department of Energy through its Triad contractor. Interested parties can engage through Los Alamos National Laboratory’s licensing program, with inquiries directed to licensing@lanl.gov, and proposals must be submitted by December 23, 2026. The technology is not being developed externally by LANL, but is available for commercialization by industry partners seeking to advance sustainable metal recovery solutions.

General Info

Engineered Lanmodulin protein selectively captures and concentrates rare earths via self-assembling condensates for sustainable, reusable recovery.

Agency

Department Of Energy → Triad - DOE ContractorView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Los Alamos, NM, 87545, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

special-notice

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Energy → Triad - DOE Contractor
Contacts2 people available
OfficeColumbus, OH, 43201, USA
Organization / Agency
Department Of Energy → Triad - DOE Contractor
View Agency Profile
Office AddressColumbus, OH, 43201, USA
Contacts
Marc Witkowski
Lindsay Augustyn

Full Description

Show more

Protein-Based Rare Earth Recovery via Condensation from scientists at Los Alamos National Laboratory offers a cleaner, flexible way to capture and concentrate rare earth elements from complex liquid mixtures by using a bio-inspired protein system that gathers target metals into separable clusters. The approach is designed to reduce reliance on harsher processing methods while supporting more resilient supply chains for critical materials used across energy, electronics, transportation and advanced manufacturing markets. Because the system is genetically modular, the same platform may be adapted with different Lanmodulin-type metal-binding variants to support selective capture needs across varied feedstocks.


How it Works


The technology modifies Lanmodulin, a protein known for strong rare earth element binding, by adding an “encapsulation peptide" to the N-terminus of the protein. Once the engineered protein binds rare earth elements in solution, the resulting protein-metal complexes can be triggered for self-assemble into biomolecular condensates, which are larger clusters that can be removed from the liquid. The material can then be separated and concentrated through various means–such as centrifugation, filtration, and sedimentation–reducing the need for immobilizing the protein on a column or other fixed support.


Technical Description


Rare earth elements are important to modern technologies; yet, processing and purification can be difficult and environmentally damaging. Protein-Based Rare Earth Recovery via Condensation addresses that problem through EP-LanM, an engineered version of Lanmodulin that changes its material state when rare earth elements are present. Rather than focusing only on changing which rare earth elements Lanmodulin binds, this technology changes how the protein behaves after binding, turning dissolved protein-metal complexes into recoverable droplets. The metals can be harvested from the protein droplets, and the resultant free-protein itself can be recycled into iterative separations.


The protein architecture is modular, with the encapsulation peptide fused to Lanmodulin so the protein can self-assemble in response to rare earth element binding. The assembled EP-LanM-rare earth complexes can be captured through simple centrifugation, filtration, or sedimentation, which may simplify processing compared with approaches that require immobilization on a column. The modular design may also support use with other Lanmodulin derivatives that have been designed for specific rare earth affinities, creating a path toward tailored separation strategies — without requiring a full redesign of the recovery concept.


Advantages


  • Uses a bio-based protein system for rare earth element capture
  • Concentrates rare earth elements from complex mixtures
  • Enables separation after droplet formation
  • Avoids the need for protein immobilization in a column-based format
  • Supports modular adaptation with different Lanmodulin derivatives
  • Aligns with demand for more environmentally conscious critical-material recovery methods
  • Allows recovery and recycling of input protein

Market Applications


  • Critical Minerals Recovery (rare earth concentration, mixed metal streams)
  • Mining and Mineral Processing (process waters, low-grade sources)
  • Waste Recycling (recovered components, mixed recycling streams)
  • Environmental Remediation (metal-bearing waters, industrial residuals)
  • Biomanufacturing and Bioseparation (engineered protein recovery tools, modular capture systems)


Development Status: TRL 3


U.S. Patent pending


LA-UR-26-25158



LANL Tech Partnerships: Unlock the Innovative Potential


Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.


LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov.


Note: This is not a call for external services for the development of this technology.


https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology


m.lanl.gov/tech-search



Similar Contracts

NAICS: 541714
New
Federal
Notice of Intent contact activation pathway function blocking antibody AB023The Defense Health Agency, through its Contracting Activity, intends to award a sole-source contract to Oregon Health & Science University for the supply of the contact activation pathway function blocking antibody AB023, in support of the United States Army Institute of Surgical Research. This determination follows a prior Request for Information that received no responses, leading the government to conclude that OHSU is the only viable source capable of fulfilling this specialized requirement. The contract action is classified under NAICS code 541714, which pertains to research and development in the physical, engineering, and life sciences, with a size standard of 1,000 employees. The solicitation number is HT9426-26-NOI-WS03, and while this notice is not a solicitation for competitive bids, responsible parties may still submit capability information by July 9, 2026, to demonstrate their ability to meet the requirement, though such submissions will only inform the government’s decision on competitiveness and carry no cost reimbursement. All submissions must be sent via email to the designated point of contact by the deadline, and the government retains full discretion to proceed with non-competitive award. The primary performance location is in San Antonio, Texas, while the contracting office is based in Fort Detrick, Maryland.
Defense Health Agency

POSTED

1 day ago

DEADLINE

in 15 days
View Details
NAICS: 541714
New
Federal
Vector-borne Disease Agent Surveillance Research & Development in External Proficiency TestingThe contract seeks a Firm-Fixed Price award for research, development, and validation of field-expedient external proficiency testing procedures to detect pathogens in arthropods, specifically mosquitoes, using non-infectious agents to minimize risk and ensure safety. The work, titled Vector-borne Disease Agent Surveillance Research & Development in External Proficiency Testing, is managed by the Defense Health Agency under the Department of Defense and is assigned NAICS code 541714 for Research and Development in Biotechnology. The performance period spans one year from September 30, 2026, to September 29, 2027, with key deliverables including a kickoff meeting within 15 days of award, a draft and final written manual for safe proficiency testing, a comprehensive validation report documenting accuracy, precision, analytical sensitivity, and specificity, and a results package with statistically valid data from at least 60 samples. All work is unclassified, with Controlled Unclassified Information (CUI) handling applicable, while Personally Identifiable Information and Protected Health Information requirements do not apply. The Government intends to obtain unlimited rights in all data and deliverables to support force health protection and potential transition to other entities. Submissions must be structured into two volumes: Volume I, the Technical Capabilities section, limited to ten pages, detailing technical expertise in external quality assurance, quality control measures, sourcing, delivery approach, and schedule adherence; and Volume II, the Price section, with no page limit but requiring unit and total prices for the single contract line item. Quotes must be submitted electronically by June 16, 2026, in Word, Excel, or searchable PDF format, with zip files prohibited. Offerors must maintain active SAM registration and submit completed provisions 52.219-1 and 252.204-7017. Technical proposals must achieve at least an "Acceptable" rating and the proposed price must be deemed complete and reasonable as mandatory pass/fail gates; award will be made based on the most advantageous offer considering both technical merit and price, without negotiations. Contract administration relies on the Wide Area WorkFlow system for payments, with tailored instructions for cost-type and fixed-price deliverables, and is governed by a Quality Assurance Surveillance Plan that defines performance standards, surveillance frequency, and defect thresholds. The Contracting Officer’s Representative provides oversight but lacks authority to modify contract terms. Compliance with clauses on convict labor, prohibitions on inverted corporations, confidentiality agreements, trafficking in
Defense Health Agency

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 541714
New
Grant
Site-Specific Clinical Research Study ExecutionThe contract requires the design and execution of a focused clinical research project examining outcomes related to spinal cord injury in the domains of health, employment, or community living. The awardee must obtain IRB approval, recruit eligible participants, deliver the assigned intervention, and systematically measure outcomes using validated methods. This work is conducted as a subcontract under the Administration for Community Living within the Department of Health and Human Services and is aligned with research priorities aimed at improving quality of life for individuals with spinal cord injuries. All activities must adhere to ethical standards and federal research guidelines, with full responsibility for study implementation resting with the contractor. The project is governed under NAICS code 541714, indicating a focus on research and development in the social sciences and humanities. The solicitation was posted on June 22, 2026, with responses due by July 29, 2026. There is no set-aside designation specified, and the place of performance details are not provided, implying flexibility in location as long as the research objectives are met. The award is structured as a subcontract, suggesting it supports broader federal efforts to advance SCI recovery and integration outcomes. The contractor must demonstrate capacity in human subjects research, clinical study logistics, and outcome measurement to successfully fulfill the scope.
Administration For Community Living

POSTED

2 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
Infinium Global Diversity Array Kits.The National Institutes of Health, through its Office of Logistics and Operations, is conducting a non-competitive, sole-source acquisition under FAR Part 13 for technical support services related to the Infinium Methylation Global Diversity Array Kits, with a simplified acquisition ceiling of $350,000. This procurement is justified based on Illumina, Inc.’s exclusive and irreplaceable capability to provide specialized technical support through its dedicated team of Technical Applications Scientists and Field Application Scientists, who possess unmatched expertise in troubleshooting the proprietary Infinium assay system. Only Illumina can deliver free-of-charge replacement reagents in the event of assay failure due to product performance, a critical requirement that no other vendor can meet. The acquisition is issued under NAICS code 541714 and is open to businesses certifying their size status as small or other than small based on the $34 million annual receipts threshold, with all offerors required to maintain active SAM registration and provide a Unique Entity ID and Taxpayer Identification Number. The contract performance location is Bethesda, Maryland, and proposals must be submitted electronically via email to the designated point of contact by the July 2, 2026 deadline. No formal evaluation factors, line items, pricing details, or packaging requirements are specified, as this is a presolicitation notice relying entirely on the unique technical capabilities of the sole source. Acceptance criteria are implicitly tied to the contractor’s ability to sustain assay performance through timely troubleshooting and replacement reagents. The contract type is unspecified, and no options, security clearances, key personnel, or organizational conflict of interest provisions are included, as the acquisition is narrowly focused on the singular technical support needs tied to Illumina’s proprietary platform.
National Institutes Of Health Olao

POSTED

2 days ago

DEADLINE

in 8 days
View Details